Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab
National : Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND) and Innovent Biologics have announced a groundbreaking partnership to exclusively license and commercialize sintilimab, an advanced PD-1 immunotherapy, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region. Cancer…